Benzinga | Nov 11, 2020 07:48AM EST

Morgan Stanley Maintains Overweight on BeiGene, Raises Price Target to $310

Morgan Stanley maintains BeiGene (NASDAQ:BGNE) with a Overweight and raises the price target from $270 to $310.